Bio-Techne Corp.

TECH ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2010 FY2009
Revenue $269.0M $264.0M
Biotechnology
Clinical Controls
Protein Platforms
Protein Sciences
Diagnostics and Genomics
Diagnostics and Spatial Biology
Other
Eliminations
Cost of Revenue $54.9M $55.9M
Gross Profit $214.1M $208.0M
Gross Margin 79.6% 78.8%
Operating Expenses
Research & Development
SG&A Expense $32.7M $33.7M
Operating Income $156.3M $150.8M
Operating Margin 58.1% 57.1%
Interest Expense
Pretax Income $156.4M
Income Tax Expense $46.7M $50.1M
Net Income $109.8M $105.2M
Net Margin 40.8% 39.9%
EPS (Basic) $0.74 $0.70
EPS (Diluted) $0.74 $0.70
Shares Outstanding (Basic) 149.0M 151.2M
Shares Outstanding (Diluted) 149.4M 151.6M
Dividends Per Share $0.26 $0.19
← Newer Page 3 of 3 Older →